Genovis
Genovis is a Swedish life science tools company that develops and markets enzyme-based products and related technologies for biopharmaceutical research, diagnostics, and drug development. Its portfolio includes SmartEnzymes, antibody labeling and glycan-remodeling technologies, and genomics reagents, with operations centered in Sweden and a U.S. subsidiary supporting North American sales.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueEnzyme-based tools used for biochemical and biophysical analysis workflows.
Technologies and reagents for antibody labeling, remodeling, and ADC workflows.
Reagents and tools for genomics research, including RNA-related applications.
Application support, customized products, and customer-specific development work.
Customers
Genovis sells to biopharmaceutical companies, biotech firms, and research organizations that need specialized tools for discovery, preclinical work, clinical development, and manufacturing. Customers use its products to simplify workflows, improve data quality, and support development of biologics, ADCs, gene therapy, and genomics applications.
Buy enzyme tools and conjugation technologies for discovery, preclinical, and clinical development.
Use ADC, gene therapy, and targeted delivery tools to build and test therapeutic candidates.
Purchase reagents and workflow tools for biochemical analysis and genomics research.
Use products to verify consistency and support production-stage analytical workflows.
Strategy
Genovis focuses on customer-driven innovation, new product launches, and deeper integration of its tools into customer workflows from discovery through manufacturing. It also uses licensing, intellectual property, and acquisitions to broaden its technology base and expand into adjacent applications such as genomics and ADC development.
Close collaboration with users helps Genovis build tools that fit real workflows and improve adoption.
Access to proprietary technology expands the addressable market and supports differentiated offerings.
Serving discovery, clinical, and manufacturing stages increases customer lifetime value and product relevance.
Geography
Genovis is headquartered in Kävlinge, Sweden, where it develops and produces enzyme products and houses central support functions. The company sells across Europe and North America through its Swedish parent and U.S. subsidiary, with local commercial representation in several key markets and a business development presence in Shanghai.
Risks
Genovis faces technology, patent, and launch-execution risk because its business depends on specialized products that must remain differentiated and work reliably in customer workflows. It also has exposure to currency movements, customer investment cycles in life science, and dependence on external production capacity for some products.
- Patent and intellectual property riskImpact: HighLikelihood: Medium
The company relies on proprietary enzyme and workflow technologies that must be protected from imitation or infringement claims.
Exposure: Core product portfolio and licensing value
- Technology and product launch riskImpact: HighLikelihood: Medium
New tools must work as expected and gain adoption in scientific workflows, or expected revenue may not materialize.
Exposure: New product pipeline
- Foreign exchange riskImpact: MediumLikelihood: High
Expenses are mainly in SEK while revenue is largely in USD and EUR, creating translation and transaction exposure.
Exposure: Operating profit and cash flow
- Customer demand cyclicalityImpact: MediumLikelihood: Medium
Life science customers may delay purchases when research or development budgets tighten.
Exposure: Order intake and launch timing
- Production dependency riskImpact: Medium
Reliance on external manufacturing capacity for some products can delay launches and constrain supply.
Exposure: Selected product lines
Accounting
Judgemental itemsAcquired technology and customer relationships must be measured at fair value and then amortized, affecting future earnings.
Impact: SEQURNA acquisition and any future M&A
Goodwill is tested for impairment and could be written down if expected cash flows from acquired businesses weaken.
Impact: Reported equity and operating results
Revenue is largely in USD and EUR while most expenses are in SEK, so exchange rates can materially affect margins and profit.
Impact: Operating profit and equity
Timing can vary depending on shipment, delivery, and any customized customer-specific work.
Impact: Quarterly comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Annovis Bio, Inc.
ANVS · Pharmaceutical Preparations
Hansa Biopharma
HNSA · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
Prevas
PREV-B · Technology
Prevas AB is a Nordic design and development company specializing in engineering, life sciences, and defense sectors.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
CellaVision
CEVI · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Arvinas, Inc
ARVN · Pharmaceutical Preparations
Last updated: 24/09/2026